N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
N-truncated Aβ4-42 is highly abundant in Alzheimer disease (AD) brain and was the first Aβ peptide discovered in AD plaques. However, a possible role in AD aetiology has largely been neglected. In the present report, we demonstrate that Aβ4-42 rapidly forms aggregates possessing a high aggregation propensity in terms of monomer consumption and oligomer formation. Short-term treatment of primary cortical neurons indicated that Aβ4-42 is as toxic as pyroglutamate Aβ3-42 and Aβ1-42. In line with these findings, treatment of wildtype mice using intraventricular Aβ injection induced significant working memory deficits with Aβ4-42, pyroglutamate Aβ3-42 and Aβ1-42. Transgenic mice expressing Aβ4-42 (Tg4-42 transgenic line) developed a massive CA1 pyramidal neuron loss in the hippocampus. The hippocampus-specific expression of Aβ4-42 correlates well with age-dependent spatial reference memory deficits assessed by the Morris water maze test. Our findings indicate that N-truncated Aβ4-42 triggers acute and long-lasting behavioral deficits comparable to AD typical memory dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As Aβ4–42 is predominantly expressed in the CA1 region in Tg4–42hom mice [21], hippocampal mRNA extracts were used for the analysis of both transgenes.”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Tg4–42 mouse model used in the present study primarily shows an intraneuronal accumulation of Aβ peptides, in particular in CA1 hippocampal neurons, and does not form overt extracellular plaques [21].”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Spatial reference memory in 5xFAD Lrp1 BE -/-mice and 5xFAD Lrp1 BE fl/fl control mice was assessed using the Morris water maze (40) by a blinded investigator as described previously (41).”
From Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier (2015) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have recently generated a transgenic mouse model (Tg4–42) that overexpresses Aβ4–42 peptides under the control of the murine neuron-specific Thy1-promoter [21].”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In brief, the human Aβ4-42 sequence is fused to the signal peptide sequence of the thyrotropin-releasing hormone and the expression is under the control of the Thy1 promoter.”
From Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedPfaffl, M. W. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.9.e36 · Cited by 7,376
Developments of a water-maze procedure for studying spatial learning in the rat
Morris, R. (1984) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(84)90007-4 · Cited by 7,180
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 2×
“1 3 There is increasing evidence that the primary insult in AD is caused by oligomeric species derived from fulllength Aβ1-42 impairing synaptic functions [14, 67].”
BackgroundMorris water maze: procedures for assessing spatial and related forms of learning and memory
Vorhees, C. V., & Williams, M. T. (2006) · Nature Protocols · doi:10.1038/nprot.2006.116 · Cited by 4,629
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 6×
“In 5XFAD, another mouse model expressing mutant APP and PS1 [42], a heterogeneous mixture of full-length, N-truncated and modified Aβ peptides, including Aβ4-42, were found [70].”
BackgroundInfluentialDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“Small, soluble Aβ1-42 oligomers ranging in size from dimers to dodecamers have been found as key drivers of neurotoxicity in vitro and in vivo [6, 28, 30, 43, 61, 71].”
Background
Cited by
Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier
Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., Baches, S., Vandenbroucke, R. E., Bouter, Y., Prikulis, I., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81108 · Cited by 477
“Next, we investigated how brain endothelial LRP1 deficiency affects AD-related behavior by examining spatial learning and memory (40, 41).”
Self-citationThe role of astrocytes in amyloid production and Alzheimer's disease
Frost, G. R., & Li, Y.-M. (2017) · Open Biology · doi:10.1098/rsob.170228 · Cited by 435
Truncated and modified amyloid-beta species
Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt258 · Cited by 341
Bayer, T. A., & Wirths, O. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1287-x · Cited by 165
Self-citationRichard, B. C., Kurdakova, A., Baches, S., Bayer, T. A., Weggen, S., & Wirths, O. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143120 · Cited by 142
Self-citationA Functional Role for Aβ in Metal Homeostasis? N‐Truncation and High‐Affinity Copper Binding
Mital, M., Wezynfeld, N. E., Frączyk, T., Wiloch, M. Z., Wawrzyniak, U. E., Bonna, A., Tumpach, C., Barnham, K. J., Haigh, C. L., Bal, W., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201502644 · Cited by 131
Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys, J., Valverde, A., & Checler, F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r118.003999 · Cited by 114
Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
Bayer, T. A. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 94
Self-citationPhosphorylation modifies the molecular stability of β-amyloid deposits
Rezaei‐Ghaleh, N., Amininasab, M., Kumar, S., Walter, J., & Zweckstetter, M. (2016) · Nature Communications · doi:10.1038/ncomms11359 · Cited by 102
Self-citationThe Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease
Drew, S. C. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00317 · Cited by 91
Gunn, A. P., Wong, B. X., Johanssen, T., Griffith, J. C., Masters, C. L., Bush, A. I., Barnham, K. J., Duce, J. A., & Cherny, R. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655183 · Cited by 83
Dal Prà, I., Chiarini, A., Gui, L., Chakravarthy, B., Pacchiana, R., Gardenal, E., Whitfield, J. F., & Armato, U. (2015) · The Neuroscientist · doi:10.1177/1073858414529828 · Cited by 74
Hüttenrauch, M., Brauß, A., Kurdakova, A., Borgers, H., Klinker, F., Liebetanz, D., Salinas-Riester, G., Wiltfang, J., Klafki, H. W., & Wirths, O. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.65 · Cited by 78
Self-citationAβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition
Cabrera, E., Mathews, P., Mezhericher, E., Beach, T. G., Deng, J., Neubert, T. A., Rostagno, A., & Ghiso, J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.005 · Cited by 78
Bouter, Y., Kacprowski, T., Weissmann, R., Dietrich, K., Borgers, H., Brauß, A., Sperling, C., Wirths, O., Albrecht, M., Jensen, L. R., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00075 · Cited by 76
Self-citationSchönherr, C., Bien, J., Isbert, S., Wichert, R., Prox, J., Altmeppen, H., Kumar, S., Walter, J., Lichtenthaler, S. F., Weggen, S., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0084-5 · Cited by 76
18F-FDG-PET Detects Drastic Changes in Brain Metabolism in the Tg4–42 Model of Alzheimer’s Disease
Bouter, C., Henniges, P., Franke, T. N., Irwin, C., Sahlmann, C. O., Sichler, M. E., Beindorff, N., Bayer, T. A., & Bouter, Y. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00425 · Cited by 82
Self-citationNeuron Loss in Alzheimer’s Disease: Translation in Transgenic Mouse Models
Wirths, O., & Zampar, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218144 · Cited by 75
“In good agreement with the abovementioned results in models expressing only specific Aβ peptide variants, these mice do not develop overt extracellular amyloid pathology [65] but robust intraneuronal Aβ accumulation, mainly in the hippocampus (Figure 2).”
BackgroundResultSelf-citationBouter, Y., López‐Noguerola, J. S., Tucholla, P., Crespi, G. A. N., Parker, M. W., Wiltfang, J., Miles, L. A., & Bayer, T. A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1489-x · Cited by 79
Self-citationParodi‐Rullán, R., Ghiso, J., Cabrera, E., Rostagno, A., & Fossati, S. (2020) · Aging Cell · doi:10.1111/acel.13258 · Cited by 69
Wirths, O., Walter, S., Kraus, I., Klafki, H. W., Stazi, M., Oberstein, T. J., Ghiso, J., Wiltfang, J., Bayer, T. A., & Weggen, S. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0309-z · Cited by 64
Self-citationWalter, S., Jumpertz, T., Hüttenrauch, M., Ogorek, I., Gerber, H., Storck, S. E., Zampar, S., Dimitrov, M., Lehmann, S., Lepka, K., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1929-5 · Cited by 65
Self-citationAstrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides
Oberstein, T. J., Spitzer, P., Klafki, H.-W., Linning, P., Neff, F., Knölker, H.-J., Lewczuk, P., Wiltfang, J., Kornhuber, J., & Maler, J. M. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.031 · Cited by 59
Curdt, N., Schmitt, F. W., Bouter, C., Iseni, T., Weile, H. C., Altunok, B., Beindorff, N., Bayer, T. A., Cooke, M. B., & Bouter, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-09270-1 · Cited by 68
Self-citationAlzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
Antonios, G., Borgers, H., Richard, B. C., Brauß, A., Meißner, J., Weggen, S., Pena, V., Pillot, T., Davies, S. L., Bakrania, P., et al. (2015) · Scientific Reports · doi:10.1038/srep17338 · Cited by 61
Self-citationStazi, M., & Wirths, O. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02120-z · Cited by 59
Self-citationSchleicher, E. M., Ott, F. W., Müller, M., Silcher, B., Sichler, M. E., Löw, M. J., Wagner, J. M., & Bouter, Y. (2019) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2019.00094 · Cited by 65
Self-citationCuII Binding Properties of N-Truncated Aβ Peptides: In Search of Biological Function
Stefaniak, E., & Bal, W. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b01399 · Cited by 60
Altered neurogenesis in mouse models of Alzheimer disease
Wirths, O. (2017) · Neurogenesis · doi:10.1080/23262133.2017.1327002 · Cited by 51
Self-citationAntonios, G., Saiepour, N., Bouter, Y., Richard, B. C., Paetau, A., Verkkoniemi-Ahola, A., Lannfelt, L., Ingelsson, M., Kovacs, G. G., Pillot, T., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-56 · Cited by 53
“Interestingly, as assessed using the Morris water maze test, the hippocampus-specific expression of Aβ4–42 alone correlated with age-dependent spatial reference memory deficits [34].”
BackgroundMethodResultSelf-citationHeggland, I., Storkaas, I. S., Soligard, H., Kobro‐Flatmoen, A., & Witter, M. P. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.12876 · Cited by 60
Amyloidogenicity and toxicity of the reverse and scrambled variants of amyloid‐β 1‐42
Vadukul, D. M., Gbajumo, O., Marshall, K. E., & Serpell, L. C. (2017) · FEBS Letters · doi:10.1002/1873-3468.12590 · Cited by 58
18F-FDG-PET in Mouse Models of Alzheimer's Disease
Bouter, C., & Bouter, Y. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00071 · Cited by 59
Self-citationCalcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease
Chiarini, A., Armato, U., Liu, D., & Dal Prà, I. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00134 · Cited by 51
Portelius, E., Lashley, T., Westerlund, A., Persson, R., Fox, N. C., Blennow, K., Revesz, T., & Zetterberg, H. (2015) · Neurodegenerative Diseases · doi:10.1159/000369465 · Cited by 50
Cu II Binding to Various Forms of Amyloid‐β Peptides: Are They Friends or Foes?
Borghesani, V., Aliès, B., & Hureau, C. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201700776 · Cited by 59
The continuum between neurodegeneration, brain plasticity, and movement: a critical appraisal
Schirinzi, T., Canevelli, M., Suppa, A., Bologna, M., & Marsili, L. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0011 · Cited by 52
Qian, Y., Yin, J., Hong, J., Li, G., Zhang, B., Liu, C., Wan, Q., & Chen, L. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0598-3 · Cited by 48
Role of Hippocampal Lipocalin-2 in Experimental Diabetic Encephalopathy
Bhusal, A., Rahman, M., Lee, I.-K., & Suk, K. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00025 · Cited by 49
Giesers, N. K., & Wirths, O. (2020) · ASN Neuro · doi:10.1177/1759091420925356 · Cited by 47
“The generation of the Tg4-42 mouse model has been previously described (Bouter et al., 2013).”
BackgroundMethodSelf-citationAmyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer’s Disease
Campos‐Peña, V., Pichardo-Rojas, P. S., Sánchez-Barbosa, T., Ortíz-Islas, E., Rodríguez-Pérez, C. E., Montes, P., Ramos-Palacios, G., Silva‐Adaya, D., Quintana, R. V., Cerna-Cortés, J. F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012092 · Cited by 47
Schwab, S. K., Shearer, J., Conklin, S. E., Aliès, B., & Haas, K. L. (2015) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2015.12.021 · Cited by 47
Mobed, A., & Hasanzadeh, M. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.05.257 · Cited by 50
Jakobsen, J. E., Johansen, M. G., Schmidt, M., Liu, Y., Li, R., Callesen, H., Melnikova, M., Habekost, M., Matrone, C., Bouter, Y., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160408 · Cited by 46
Self-citationDonecopride, a Swiss army knife with potential against Alzheimer's disease
Rochais, C., Lecoutey, C., Hamidouche, K., Giannoni, P., Gaven, F., Cem, E., Mignani, S. M., Baranger, K., Fréret, T., Bockaert, J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14964 · Cited by 46
Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease
Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44
Self-citationRapid amyloid‐β oligomer and protofibril accumulation in traumatic brain injury
Abu Hamdeh, S., Waara, E. R., Möller, C., Söderberg, L., Basun, H., Alafuzoff, I., Hillered, L., Lannfelt, L., Ingelsson, M., & Marklund, N. (2018) · Brain Pathology · doi:10.1111/bpa.12532 · Cited by 41
Turn Plasticity Distinguishes Different Modes of Amyloid-β Aggregation
Rezaei‐Ghaleh, N., Amininasab, M., Giller, K., Kumar, S., Stuendl, A., Schneider, A., Becker, S., Walter, J., & Zweckstetter, M. (2014) · Journal of the American Chemical Society · doi:10.1021/ja411707y · Cited by 44
Self-citationStazi, M., Lehmann, S., Sakib, M. S., Pena‐Centeno, T., Büschgens, L., Fischer, A., Weggen, S., & Wirths, O. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04062-8 · Cited by 43
Self-citationWang, Q., Wang, C., Shu, Z., Chan, K., Huang, S.-M., Li, Y., Xiao, Y., Wu, L., Kuang, H., & Sun, X. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.11.017 · Cited by 41
Icariin ameliorate Alzheimer’s disease by influencing SIRT1 and inhibiting Aβ cascade pathogenesis
Chuang, Y. C., Van, I., Zhao, Y., & Xu, Y. (2021) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2021.102014 · Cited by 45
Relevance of transgenic mouse models for Alzheimer's disease
(2021) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2020.07.007 · Cited by 35
Interplay between Copper, Neprilysin, and N-Truncation of β-Amyloid
Mital, M., Bal, W., Frączyk, T., & Drew, S. C. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b00391 · Cited by 35
Franke, T. N., Irwin, C., Bayer, T. A., Brenner, W., Beindorff, N., Bouter, C., & Bouter, Y. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00529 · Cited by 38
Self-citationMatuszyk, M. M., Garwood, C. J., Ferraiuolo, L., Simpson, J. E., Staniforth, R. A., & Wharton, S. B. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15538 · Cited by 38
Oumata, N., Lu, K., Teng, Y., Cavé, C., Yu, P., Galons, H., & Roques, B. P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114578 · Cited by 38
Streltsov, V. A., Ekanayake, R. S. K., Drew, S. C., Chantler, C. T., & Best, S. P. (2018) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.8b01255 · Cited by 37
Quintanilla‐Sánchez, C., Schmitt, F. W., Curdt, N., Westhoff, A. C., Bänfer, I. W. H., Bayer, T. A., & Bouter, Y. (2023) · Biomedicines · doi:10.3390/biomedicines11020599 · Cited by 35
Self-citationReinert, J., Martens, H., Hüttenrauch, M., Kolbow, T., Lannfelt, L., Ingelsson, M., Paetau, A. E., Verkkoniemi‐Ahola, A., Bayer, T. A., & Wirths, O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131373 · Cited by 43
Self-citationBakrania, P., Hall, G., Bouter, Y., Bouter, C., Beindorff, N., Cowan, R. H., Davies, S. L., Price, J., Mpamhanga, C., Love, E. A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01385-7 · Cited by 32
Self-citationSynaptic Alterations in Mouse Models for Alzheimer Disease—A Special Focus on N-Truncated Abeta 4-42
Dietrich, K., Bouter, Y., Müller, M., & Bayer, T. A. (2018) · Molecules · doi:10.3390/molecules23040718 · Cited by 31
Self-citationCitrullination of Amyloid-β Peptides in Alzheimer’s Disease
Mukherjee, S., Perez, K. A., Dubois, C., Nisbet, R. M., Li, Q., Varghese, S., Jin, L., Birchall, I. E., Streltsov, V. A., Vella, L. J., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00474 · Cited by 32
Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids
Galozzi, S., Marcus, K., & Barkovits, K. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1065183 · Cited by 32
Chemical imaging delineates Aβ plaque polymorphism across the Alzheimer’s disease spectrum
Koutarapu, S., Ge, J., Dulewicz, M., Srikrishna, M., Szadziewska, A., Wood, J. I., Blennow, K., Zetterberg, H., Michno, W., Ryan, N. S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59085-7 · Cited by 32
Breydo, L., Redington, J., & Uversky, V. N. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.08.011 · Cited by 30
Acetylation of Aβ42 at Lysine 16 Disrupts Amyloid Formation
Adhikari, R., Yang, M., Saikia, N., Dutta, C., Alharbi, W. F. A., Shan, Z. J., Pandey, R., & Tiwari, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00069 · Cited by 29
Wang, C., Xiao, Y., Yang, B., Wang, Z., Wu, L., Su, X., Brantner, A. H., Kuang, H., & Wang, Q. (2014) · Fitoterapia · doi:10.1016/j.fitote.2014.04.007 · Cited by 29
Summers, K. L., Roseman, G. P., Schilling, K. M., Dolgova, N. V., Pushie, M. J., Sokaras, D., Kröll, T., Harris, H. H., Millhauser, G. L., Pickering, I. J., et al. (2022) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.2c01694 · Cited by 30
Piechotta, A., Parthier, C., Kleinschmidt, M., Gnoth, K., Pillot, T., Lues, I., Demuth, H., Schilling, S., Rahfeld, J., & Stubbs, M. T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.777839 · Cited by 29
Self-citationShepherd, A. L., Zhang, T. D., Zeleznikow-Johnston, A., Hannan, A. J., & Burrows, E. L. (2018) · Brain Plasticity · doi:10.3233/bpl-180076 · Cited by 32
Bouter, C., Irwin, C., Franke, T. N., Beindorff, N., & Bouter, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.745064 · Cited by 30
Self-citationGuzmán, E. A., Bouter, Y., Richard, B. C., Lannfelt, L., Ingelsson, M., Paetau, A. E., Verkkoniemi‐Ahola, A., Wirths, O., & Bayer, T. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-13 · Cited by 33
Self-citationPhosphorylation Interferes with Maturation of Amyloid-β Fibrillar Structure in the N Terminus
Rezaei‐Ghaleh, N., Kumar, S., Walter, J., & Zweckstetter, M. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.728956 · Cited by 28
Self-citationStefaniak, E., Atrián‐Blasco, E., Goch, W., Sabater, L., Hureau, C., & Bal, W. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202004484 · Cited by 33
Brain Region-Specific Differences in Amyloid-β Plaque Composition in 5XFAD Mice
Bader, A. S., Gnädig, M.-U., Fricke, M., Büschgens, L., Berger, L. J., Klafki, H., Meyer, T., Jahn, O., Weggen, S., & Wirths, O. (2023) · Life · doi:10.3390/life13041053 · Cited by 33
Self-citationAmyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies
Dileep, K. V., & Chandra, R. (2019) · Current Drug Targets · doi:10.2174/1389450120666190806153206 · Cited by 27
Proteolytic α-Synuclein Cleavage in Health and Disease
Bluhm, A., Schrempel, S., von Hörsten, S., Schulze, A., & Roßner, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115450 · Cited by 27
Marengo, L., Armbrust, F., Schoenherr, C., Storck, S. E., Schmitt, U., Zampar, S., Wirths, O., Altmeppen, H. C., Glatzel, M., Kaether, C., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04205-5 · Cited by 26
Self-citationAntibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
Sumner, I. L., Edwards, R. A., Asuni, A. A., & Teeling, J. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00254 · Cited by 24
Goch, W., & Bal, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170749 · Cited by 25
N-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
Rostagno, A. A., Cabrera, E., Lashley, T., & Ghiso, J. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00303-3 · Cited by 24
Alzheimer’s Disease—A Panorama Glimpse
Zhao, L. N., Lu, L., Chew, L. Y., & Mu, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150712631 · Cited by 30
Dey, C., Roy, M., Pal, P., Ghosh, R., & Dey, S. G. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00544b · Cited by 24
Domingo, G., Benussi, L., Saraceno, C., Bertuzzi, M., Nicsanu, R., Longobardi, A., Bellini, S., Cagnotto, A., Salmona, M., Binetti, G. G., et al. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708119 · Cited by 22
A Functional Role for Aβ in Metal Homeostasis? N‐Truncation and High‐Affinity Copper Binding
Mital, M., Wezynfeld, N. E., Frączyk, T., Wiloch, M. Z., Wawrzyniak, U. E., Bonna, A., Tumpach, C., Barnham, K. J., Haigh, C. L., Bal, W., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201502644 · Cited by 23
Differential Modulation of the Aggregation of N‐Terminal Truncated Aβ using Cucurbiturils
Gao, L., Yang, W., Zhao, Y., Chen, Y., Hong, L., & Li, Y. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201802655 · Cited by 21
Goldblatt, G., Cilenti, L., Matos, J. O., Lee, B., Ciaffone, N., Wang, Q. X., Tétard, L., Teter, K., & Tatulian, S. A. (2017) · FEBS Journal · doi:10.1111/febs.14058 · Cited by 21
Yang, B., Guo, J., Li, Z., Wang, C., Wang, Z., Wang, Q., & Kuang, H. (2016) · Chemistry & Biodiversity · doi:10.1002/cbdv.201500311 · Cited by 20
Lin, J., Shao, X., Shi, T., Wang, H., Zhang, P., Zhou, Y., Liu, N., He, Y., Fang, D., Shi, Y., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01075-5 · Cited by 21
Goldblatt, G., Matos, J. O., Gornto, J., & Tatulian, S. A. (2015) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp03343h · Cited by 22
The Hidden Role of Non-Canonical Amyloid β Isoforms in Alzheimer’s Disease
Busch, L., Eggert, S., Endres, K., & Bufe, B. (2022) · Cells · doi:10.3390/cells11213421 · Cited by 22
Reduced Acoustic Startle Response and Prepulse Inhibition in the Tg4-42 Model of Alzheimer’s Disease
Sichler, M. E., Löw, M. J., Schleicher, E. M., Bayer, T. A., & Bouter, Y. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190132 · Cited by 20
Self-citationPinpointing the locus of GABAergic vulnerability in Alzheimer’s disease
Melgosa-Ecenarro, L., Doostdar, N., Radulescu, C. I., Jackson, J., & Barnes, S. J. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.06.017 · Cited by 22
Bayer, T. A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.710579 · Cited by 20
Self-citationHartlage‐Rübsamen, M., Bluhm, A., Piechotta, A., Linnert, M., Rahfeld, J., Demuth, H., Lues, I., Kuhn, P., Lichtenthaler, S. F., Roßner, S., et al. (2018) · Molecules · doi:10.3390/molecules23040924 · Cited by 20
Characterization of a Mouse Model of Alzheimer’s Disease Expressing Aβ4-42 and Human Mutant Tau
Zampar, S., & Wirths, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105191 · Cited by 18
“We have recently generated a transgenic mouse model (Tg4–42) that overexpresses Aβ4–42 peptides under the control of the murine neuron-specific Thy1-promoter [21].”
BackgroundMethodInfluentialSelf-citationLópez‐Noguerola, J. S., Gießen, N. M.-E., Ueberück, M., Meißner, J. N., Pelgrim, C. E., Adams, J., Wirths, O., Bouter, Y., & Bayer, T. A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00064 · Cited by 22
Self-citationSavastano, A., Klafki, H., Haußmann, U., Oberstein, T. J., Müller, P., Wirths, O., Wiltfang, J., & Bayer, T. A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150394 · Cited by 21
Self-citationBinding Modes of Phthalocyanines to Amyloid β Peptide and Their Effects on Amyloid Fibril Formation
Valiente‐Gabioud, A. A., Riedel, D., Outeiro, T. F., Menacho-Márquez, M., Griesinger, C., & Fernández, C. O. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.01.003 · Cited by 18
The prion protein regulates beta-amyloid-mediated self-renewal of neural stem cells in vitro
Collins, S. J., Tumpach, C., Li, Q., Lewis, V., Ryan, T. M., Roberts, B. R., Drew, S. C., Lawson, V., & Haigh, C. L. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0067-4 · Cited by 17
Metadata
- Authors
- Bouter, Y., Dietrich, K., Wittnam, J. L., Rezaei-Ghaleh, N., Pillot, T., Papot-Couturier, S., Lefebvre, T., Sprenger, F., Wirths, O., Zweckstetter, M., & Bayer, T. A.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- German Center for Neurodegenerative Diseases (DE)
- Corresponding author
- Bayer, Thomas A.
- Venue
- Acta Neuropathologica
- Published
- 2013-05-18
- Volume
- 126
- Issue
- 2
- Pages
- 189-205
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC3722453
- OpenAlex
- W2142807222
- Cited by
- 175
- References
- 71
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 22 · 2020: 16 · 2019: 16 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 17 · 2014: 12 · 2013: 2
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- DZNE Pub (submittedVersion, other-oa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid fibril formation, amyloid-beta 42, neurotoxicity, working memory deficits, spatial reference memory, transgenic mice, amyloid plaques, behavioral deficits
- MeSH terms
- Alzheimer Disease, Amyloid, Animals, Behavior, Animal, Female, Fetus, Humans, Injections, Intraventricular, Male, Mice, Inbred C57BL, Mice, Transgenic, Molecular Weight, Nerve Degeneration, Neurons, Pregnancy, Solubility, Space Perception, Amyloid beta-Peptides, Rats, Wistar, Maze Learning, Microscopy, Electron, Transmission, Mice, Rats, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.